A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003684/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)
提供机构：
Vivli
创建时间：
2019-04-12
